|
|
|
Effect of Probucol combined with Rosuvastatin on inflammatory mediators and related laboratory indexes in patients with cerebral infarction
ZHANG Yi-dan XU Chu-chuan YU Zi-wen LIU Lin |
| ZHANG Yi-dan XU Chu-chuan YU Zi-wen LIU Lin |
| Department of Neurology, the First Affiliated Hospital of Xiamen University, Fujian Province, Xiamen 361003, China |
|
|
|
|
Abstract Objective To explore the effect of Probucol combined with Rosuvastatin on inflammatory mediators and related laboratory indicators in patients with cerebral infarction. Methods A total of 106 patients with cerebral infarction admitted to the First Affiliated Hospital of Xiamen University from December 2019 to February 2021 were selected and divided into control group (53 cases) and observation group (53 cases) according to the random number table method.The control group was treated with Rosuvastatin, and the observation group was treated with Probucol on the basis of the control group. The inflammatory mediators, serum neuron-specific enolase (NSE), central nervous system-specific protein (S100β), human chitinase protein 40 (YKL-40) and blood lipid levels were compared between the two groups.Results After treatment in the observation group, tumor necrosis factor-α (TNF-α), procalcitonin (PCT), high-sensitivity C-reactive protein (hs-CRP), interleukin-6 (IL-6) and matrix metalloproteinase 9 (MMP-9) level were lower than those in the control group, the levels of NSE, S100β, and YKL-40 were lower than those in the control group, and the levels of total cholesterol (TG), total cholesterol (TC), and low-density lipoprotein (LDL-C) were lower those in the control group, high-density lipoprotein (HDL-C) was higher than that in the control group, the differences were statistically significant (P<0.05); the difference between the two groups of adverse reactions was not statistically significant (P>0.05). Conclusion Probucol combined with Rosuvastatin treatment in patients with cerebral infarction can effectively reduce inflammation, reduce nerve damage, regulate blood lipid levels, and promote neurological function improvement.It is safe and reliable.
|
|
|
|
|
|
| Cite this article: |
|
ZHANG Yi-dan,XU Chu-chuan,YU Zi-wen, et al. Effect of Probucol combined with Rosuvastatin on inflammatory mediators and related laboratory indexes in patients with cerebral infarction
ZHANG Yi-dan XU Chu-chuan YU Zi-wen LIU Lin [J]. 中国当代医药, 2021, 28(34): 43-45转53.
|
|
|
|
| URL: |
| http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I34/43 |
| [1] |
刘满卓，张笑娣，王慧，等.阿托伐他汀联合普罗布考对脑梗死患者Ox-LDL 及疗效的影响[J].河北医药，2019，41（17）：2632-2634，2638.
|
| [2] |
李军.丁苯酞联合阿替普酶对老年急性脑梗死患者血清BNP，NSE，S100β 水平的影响[J].药物生物技术，2019，26（2）：140-144.
|
| [3] |
段朝龙，荣鹏，孙敏，等.普罗布考联合瑞舒伐他汀对冠心病 PCI 术后病人肾功能及 MCP-1，sICAM-1，sVCAM 水平的影响[J].中西医结合心脑血管病杂志，2019，17（22）：3469-3473.
|
| [4] |
宗艳杰，谷玉静，钱娜，等.普罗布考联合阿托伐他汀治疗老年脑梗死的疗效观察[J].神经损伤与功能重建，2020，15（1）：44-46.
|
| [5] |
中华医学会神经病学分会脑血管病学组急性缺血性脑卒中诊治指南撰写组.中国急性缺血性脑卒中诊治指南2010[J].中国临床医生，2011，43（2）：146-153.
|
| [6] |
华军，曾兆雲，饶朝楷.普罗布考联合阿托伐他汀对大动脉源性脑梗死患者血液黏度、TCD 指标及颈动脉斑块稳定性的影响[J].贵州医药，2019，43（10）：1572-1573.
|
| [7] |
胡武明，况晓东，徐剑，等.阿托伐他汀联合普罗布考对亚临床动脉粥样硬化患者的影响研究[J].中国预防医学杂志，2019，20（10）：988-991.
|
| [8] |
时宏娟，张晓俊，陈菲，等.普罗布考联合阿托伐他汀强化治疗颈内动脉颅外段狭窄所致短暂性脑缺血发作患者的临床疗效及其对缺血性卒中的预防效果[J].实用心脑肺血管病杂志，2020，28（3）：97-102.
|
| [9] |
齐珊珊，付赵虎，白炜玮，等.瑞舒伐他汀联合普罗布考治疗老年脑梗死患者疗效分析[J].疑难病杂志，2018，17（6）：554-557.
|
| [10] |
黄芳，张千，张兆，等.普罗布考联合瑞舒伐他汀对脑梗死患者血脂、炎症介质等的影响[J].疑难病杂志，2018，17（2）：117-120.
|
| [11] |
魏雨雨，陈铮立.普罗布考对动脉粥样硬化性脑梗死患者神经功能和人甲壳质酶蛋白40 及血脂水平的影响[J].中国医药，2018，13（11）：1666-1669.
|
| [12] |
李美杰，姚丽娜，纪利利，等.普罗布考联合瑞舒伐他汀治疗脑梗死合并糖尿病患者颈动脉粥样硬化斑块的价值[J].现代中西医结合杂志，2018，27（26）：2934-2937.
|
| [13] |
马文娟，杨佳，赵世刚.普罗布考联合阿托伐他汀对脑梗死患者血清hs-CRP、ox-LDL、MMP-9 水平及颈动脉斑块的影响[J].河北医学，2017，23（4）：620-623.
|
| [14] |
齐珊珊，付赵虎，白炜玮，等.普罗布考联合阿托伐他汀对大动脉源性脑梗死患者血液黏度、TCD 指标及颈动脉斑块稳定性的影响[J].心血管康复医学杂志，2017，26（1）：86-90.
|
| [15] |
王佩，卢丹丹，王京，等.普罗布考对脑梗死患者氧化应激水平、尿酸及临床预后的影响[J].中国现代医学杂志，2017，27（25）：49-52.
|
|
|
|
